Reduced incidence of clinical restenosis with newer generation stents, stent oversizing, and high‐pressure deployment: Single‐operator experience

Background: Over the last 4 years, several newer generation stents have become available, promising to change the scenery of coronary angioplasty (PTCA) with its attendant restenosis rate.

[1]  W Rutsch,et al.  Heparin-coated Palmaz-Schatz stents in human coronary arteries. Early outcome of the Benestent-II Pilot Study. , 1996, Circulation.

[2]  K. Endresen,et al.  Stenting in Chronic Coronary Occlusion (SICCO): a randomized, controlled trial of adding stent implantation after successful angioplasty. , 1996, Journal of the American College of Cardiology.

[3]  P. Serruys,et al.  Asymptomatic restenosis: should we (re)intervene? An unresolved dilemma. , 1998, American heart journal.

[4]  D. Antoniucci,et al.  A clinical trial comparing primary stenting of the infarct-related artery with optimal primary angioplasty for acute myocardial infarction: results from the Florence Randomized Elective Stenting in Acute Coronary Occlusions (FRESCO) trial. , 1998, Journal of the American College of Cardiology.

[5]  D. Smyth,et al.  Direct Angioplasty for Myocardial Infarction: One-Year Experience in a Center with Surgical Back-up 220 Miles Away. , 1997, The Journal of invasive cardiology.

[6]  C. Macaya,et al.  Randomized evaluation of anticoagulation versus antiplatelet therapy after coronary stent implantation in high-risk patients: the multicenter aspirin and ticlopidine trial after intracoronary stenting (MATTIS). , 1998, Circulation.

[7]  E. Fleck,et al.  Randomized multicenter comparison of conventional anticoagulation versus antiplatelet therapy in unplanned and elective coronary stenting. The full anticoagulation versus aspirin and ticlopidine (fantastic) study. , 1998, Circulation.

[8]  P. Teirstein,et al.  A randomized comparison of coronary-stent placement and balloon angioplasty in the treatment of coronary artery disease. Stent Restenosis Study Investigators. , 1994, The New England journal of medicine.

[9]  P. Berger.  Stents with high-pressure balloon inflations and intravascular ultrasonography--applicable in all patients? , 1997, Mayo Clinic proceedings.

[10]  Epic Investigators,et al.  Use of a monoclonal antibody directed against the platelet glycoprotein IIb/IIIa receptor in high-risk coronary angioplasty. , 1994, The New England journal of medicine.

[11]  M. Hadamitzky,et al.  A randomized comparison of antiplatelet and anticoagulant therapy after the placement of coronary-artery stents. , 1996, The New England journal of medicine.

[12]  C. Di Mario,et al.  Intracoronary stent implantation in native coronary arteries and saphenous vein grafts: a consecutive experience with six types of stents without prolonged anticoagulation. , 1997, Mayo Clinic proceedings.

[13]  W Rutsch,et al.  A comparison of balloon-expandable-stent implantation with balloon angioplasty in patients with coronary artery disease. Benestent Study Group. , 1994, The New England journal of medicine.

[14]  Bruce R. Brodie,et al.  Prospective, multicenter study of the safety and feasibility of primary stenting in acute myocardial infarction : In-hospital and 30-day results of the PAMI stent pilot trial , 1998 .

[15]  P Hall,et al.  Intracoronary stenting without anticoagulation accomplished with intravascular ultrasound guidance. , 1995, Circulation.

[16]  S. Steinhubl,et al.  The duration of pretreatment with ticlopidine prior to stenting is associated with the risk of procedure-related non-Q-wave myocardial infarctions. , 1998, Journal of the American College of Cardiology.

[17]  E J Topol,et al.  Coronary morphologic and clinical determinants of procedural outcome with angioplasty for multivessel coronary disease. Implications for patient selection. Multivessel Angioplasty Prognosis Study Group. , 1990, Circulation.

[18]  T. Investigators.  Randomised placebo-controlled and balloon-angioplasty-controlled trial to assess safety of coronary stenting with use of platelet glycoprotein-IIb/IIIa blockade. , 1998, Lancet.

[19]  D. Weaver,et al.  Use of Direct Angioplasty for Treatment of Patients With Acute Myocardial Infarction in Hospitals With and Without On‐Site Cardiac Surgery , 1993, Circulation.

[20]  R. Ligon,et al.  Clopidogrel as adjunctive antiplatelet therapy during coronary stenting. , 1999, Journal of the American College of Cardiology.

[21]  M. Bell,et al.  Clopidogrel versus ticlopidine after intracoronary stent placement. , 1999, Journal of the American College of Cardiology.

[22]  E. Topol.  Randomised placebo-controlled and balloon-angioplasty-controlled trial to assess safety of coronary stenting with use of platelet glycoprotein-IIb/IIIa blockade , 1998, The Lancet.

[23]  Thomas J. Ryan,et al.  Guidelines for percutaneous transluminal coronary angioplasty. A report of the American College of Cardiology/American Heart Association Task Force on Assessment of Diagnostic and Therapeutic Cardiovascular Procedures (Committee on Percutaneous Transluminal Coronary Angioplasty). , 1993, Journal of the American College of Cardiology.

[24]  I. Penn,et al.  Coronary stenting: A global perspective , 1998 .

[25]  S. Kelsey,et al.  Long-term analysis of conventional coronary balloon angioplasty and an initial "stent-like" result. The NHLBI PTCA Registry. , 1998, Journal of the American College of Cardiology.

[26]  P. Vaitkus,et al.  The evolving costs of intracoronary stents. , 1998, American heart journal.

[27]  R E Vlietstra,et al.  ACC Expert Consensus document on coronary artery stents. Document of the American College of Cardiology. , 1998, Journal of the American College of Cardiology.

[28]  R. Califf,et al.  Randomised trial of coronary intervention with antibody against platelet IIb/IIIa iritegrin for reduction of clinical restenosis: results at six months , 1994, The Lancet.

[29]  S. Pocock,et al.  A Clinical Trial Comparing Three Antithrombotic-Drug Regimens after Coronary-Artery Stenting , 1998 .